ライフサイエンスコーパス: lumpectomy

1 correlated with the presence of carcinoma at lumpectomy.

2 s with a less than 2% chance of carcinoma at lumpectomy.

3 ng surgical accuracy and margin status after lumpectomy.

4 clinical or mammographic findings following lumpectomy.

5 gement of breast tumors judged too large for lumpectomy.

6 hy to allow accurate needle localization for lumpectomy.

7 permitted successful needle localization and lumpectomy.

8 e delivery in patients with DCIS resected by lumpectomy.

9 s had cancer in the ipsilateral breast after lumpectomy.

10 radiation therapy without chemotherapy after lumpectomy.

11 st risk reduction in the long term following lumpectomy.

12 s per timing of randomisation in relation to lumpectomy.

13 eceptor-negative cancer, and radiation after lumpectomy.

14 for any type of esophageal cancer following lumpectomy.

15 (0.66%) when compared with women that had a lumpectomy (0.14%).

16 After lumpectomy, 1,009 women were randomly assigned to TAM (n

17 52]; total knee replacement [42 313]; breast lumpectomy [18 018]; colectomy [14 074]; coronary artery

18 Tumor sites were excised at lumpectomy 2-3 weeks after cryoablation.

19 cancer patients were more likely to undergo lumpectomy (67% vs 48% of Pt/PhysD breast cancer patient

20 After lumpectomy 6952 patients were treated with brachytherapy

21 aspiration (19/59), core biopsy (39/59), or lumpectomy (8/59) underwent SLN localization.

22 Of those women who underwent lumpectomy, 86% had subsequent radiation.

23 ; 87% clinical tumor size < or = 2.0 cm; 84% lumpectomy; 87% white).

24 oregional breast cancer treated with primary lumpectomy (90 [89%]) or mastectomy (11 [11%]); 75 (74%)

25 treatment with radiotherapy after undergoing lumpectomy, 9941 patients (72.4%) completed at least 1 P

26 In patients who had a lumpectomy, a high body mass index, smoking, and a histo

27 The greatest increase in lumpectomy after preoperative therapy occurred in women

28 ral breast recurrence were 7.8% and 7.8% for lumpectomy alone and 8.0% and 9.2% for lumpectomy + RT,

29 hat the combination was more beneficial than lumpectomy alone for localized intraductal carcinoma-in-

30 th radiation therapy was more effective than lumpectomy alone for the treatment of ductal carcinoma i

31 ctomy plus radiation is more beneficial than lumpectomy alone for women with localized, mammographica

32 Median follow-up was 5.9 years for the lumpectomy alone group and 7.2 years for the lumpectomy

33 ate of TR/MM in both the lumpectomy + RT and lumpectomy alone groups.

34 ble Stage IA and IB cancer with 26.6% having lumpectomy alone versus 9.4% in the younger patients.

35 reated by lumpectomy and radiation, 30.2% by lumpectomy alone, and 2.6% with no surgery.

36 atio for death among the women who underwent lumpectomy alone, as compared with those who underwent t

37 ed treatment consisting of total mastectomy, lumpectomy alone, or lumpectomy and breast irradiation.

38 However, for patients treated with lumpectomy alone, the number of surgical procedures and

39 sses, and overall for patients who underwent lumpectomy alone.

40 f whom 46,250 (62.1%) underwent a completion lumpectomy and 28,267 (37.9%) underwent a mastectomy.

41 >F or CMF after lumpectomy and breast irradiation resulted in a low prob

42 was 14.3 percent in the women who underwent lumpectomy and breast irradiation, as compared with 39.2

43 ng of total mastectomy, lumpectomy alone, or lumpectomy and breast irradiation.

44 the NCDB data set to identify predictors of lumpectomy and CPM.

45 d between January 2007 and January 2023 with lumpectomy and ET, with or without adjuvant RT.

46 e (NCDB) were examined to evaluate trends in lumpectomy and mastectomy rates from 2005 through 2017.

47 antified from diffuse reflectance spectra of lumpectomy and mastectomy specimens using a Monte Carlo

48 Twelve patients underwent lumpectomy and postsurgical intraoperative supine MR ima

49 e breast cancer were more often treated with lumpectomy and radiation and underwent fewer mastectomie

50 ve breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the Stockholm tamox

51 reoperatively than postoperatively underwent lumpectomy and radiation therapy (67.8% v 59.8%, respect

52 cancer patients treated conservatively with lumpectomy and radiation therapy (LRT) have an estimated

53 th stages I to II breast cancer treated with lumpectomy and radiation therapy (median follow-up, 12.1

54 ral breast tumor recurrence (IBTR) following lumpectomy and radiation therapy (P = 0.001).

55 osis on the outcome of treatment with either lumpectomy and radiation therapy (RT) or mastectomy for

56 rapy, and tamoxifen was of more benefit than lumpectomy and radiation therapy alone for DCIS.

57 Lumpectomy and radiation therapy in patients with breast

58 with early-stage breast cancer treated with lumpectomy and radiation therapy, 30% to 40% will develo

59 ammograms during follow-up of patients after lumpectomy and radiation therapy.

60 without complications underwent ipsilateral lumpectomy and radiation therapy.

61 In 1992, 23.3% of cases were treated by lumpectomy and radiation, 30.2% by lumpectomy alone, and

62 s with ductal carcinoma in situ (DCIS) after lumpectomy and radiation.

63 ate follow-up, younger patients treated with lumpectomy and RT had a significantly higher rate of loc

64 sis on the outcome of treatment of DCIS with lumpectomy and RT or mastectomy were identified through

65 treatment of younger patients with DCIS with lumpectomy and RT requires careful attention to patient

66 DCIS, the influence of age on outcome after lumpectomy and RT, and the impact of age on outcome afte

67 l rates if treated by mastectomy rather than lumpectomy and RT.

68 n with clinical T1-2,N0,M0 disease underwent lumpectomy and SLN dissection.

69 negative lymph nodes who were candidates for lumpectomy and SLND.

70 All patients underwent lumpectomy and tangential whole-breast irradiation.

71 ine negative or close surgical margins after lumpectomy and to determine the factors that govern the

72 ident early-stage breast cancer treated with lumpectomy and WBI from 2008 and 2013 into 2 cohorts: (1

73 cinoma from 2012-2016 that underwent upfront lumpectomy and were found to have a positive sentinel no

74 with clinically negative nodes, planned for lumpectomy and whole breast irradiation.

75 Lumpectomy and whole-breast radiotherapy (ie, breast-con

76 nts, 43% underwent mastectomy, 53% underwent lumpectomy, and therapy of 4% of patients is unknown.

77 ears) who underwent unilateral mastectomy or lumpectomy as the primary surgery for BC were included i

78 Standard therapy was defined as lumpectomy, axillary surgery, and RT or mastectomy with

79 The only discrete palpable finding was lumpectomy bed seroma.

80 by whole breast radiation with boost to all lumpectomy beds.

81 Patients with large breasts after lumpectomy (bra size >= 36 inches or cup size >= C) or a

82 omen with tumors less than 5 cm were already lumpectomy candidates.

83 eloped within or immediately adjacent to the lumpectomy cavity and were designated as true recurrence

84 Intraoperative assessment of the lumpectomy cavity has the potential to reduce residual d

85 re (SOC) excision, pFGS was used to scan the lumpectomy cavity to guide the removal of additional sha

86 ovides equivalent local tumour control after lumpectomy compared with whole-breast irradiation.

87 valuate the worth of radiation therapy after lumpectomy concluded that the combination was more benef

88 ir physicians approach the mastectomy versus lumpectomy decision.

89 asing risk of systemic relapse, frequency of lumpectomy declined (rates for five strata in order of i

90 Surgery after initial lumpectomy declined by 16% (P < .001).

91 Additional surgery after initial lumpectomy decreased markedly from 2013 to 2015 concomit

92 Lumpectomy followed by breast irradiation continues to b

93 atio for death among the women who underwent lumpectomy followed by breast irradiation, as compared w

94 agnosed at age 42 years or younger underwent lumpectomy followed by radiotherapy at our hospital.

95 Lumpectomy followed by radiotherapy provides an appealin

96 early-stage breast cancer were managed with lumpectomy followed by RT restricted to the tumor bed us

97 lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy.

98 nized cytotoxic therapy before mastectomy or lumpectomy for advanced breast carcinoma, 56 were select

99 Just as lumpectomy for breast cancer aims at achieving oncologic

100 Rates of lumpectomy for breast cancer management in the United St

101 Eligible patients underwent lumpectomy for DCIS that was mammogram detected, size 2.

102 ent years, use of breast brachytherapy after lumpectomy for early breast cancer has increased substan

103 endly mode for delivering radiotherapy after lumpectomy for early breast cancer.

104 f patients aged 50 to 69 years who underwent lumpectomy for early-stage breast cancer with ODX RS of

105 ns who recognise the limitations of standard lumpectomy for large breast cancers, and review differen

106 Two groups of women undergoing lumpectomy for palpable breast cancer were studied, one

107 ummarise the general approach to oncoplastic lumpectomy for surgeons who recognise the limitations of

108 ved adjuvant whole-breast radiotherapy after lumpectomy for unilateral breast cancer at MROQC partici

109 o 43.8%) and an increase in those treated by lumpectomy (from 25.6% to 53.3%).

110 g in the mastectomy (4.34%) group versus the lumpectomy group (1.97%).

111 e mastectomy group and 3.2 +/- 1.6 cm in the lumpectomy group (P = 0.0001).

112 no cardiac or pulmonary complications in the lumpectomy group.

113 he risk following breast-conserving surgery (lumpectomy) has yet to be determined.

114 ing treatment, various radiation doses after lumpectomy have been used.

115 a repair, femoral hernia repair, mastectomy, lumpectomy, hip arthroplasty, knee arthroplasty, hystere

116 s support whole-breast irradiation following lumpectomy; however, with an absolute difference of less

117 yoablation could be as effective and safe as lumpectomy in cases of low-risk early-stage breast cance

118 ystectomy, inguinal hernia repair, or breast lumpectomy in healthy adults.

119 about the need for breast irradiation after lumpectomy in node-negative women with invasive breast c

120 The 67% rate of initial lumpectomy in the 3729 patient analytic sample was uncha

121 The rate of final lumpectomy increased by 13% from 2013 to 2015, accompani

122 uch people for whom further treatment beyond lumpectomy is not needed).

123 consideration of postoperative radiation if lumpectomy is performed.

124 as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certai

125 owing M-->F versus 13.4% in women treated by lumpectomy; it was 0.6% following CMF in B-19.

126 /control status and by case treatment group: lumpectomy, lumpectomy with adjuvant radiation therapy,

127 me, and surgeon attitudes toward an adequate lumpectomy margin.

128 Lumpectomy margins in breast conserving operations durin

129 and one underwent excision but had tumor at lumpectomy margins.

130 y 2016, 488 surgeons were surveyed regarding lumpectomy margins; 342 (70%) responded completely.

131 2.1-4.0 cm, >/= 4.1 cm), and surgical plan (lumpectomy, mastectomy).

132 cipants eligible for radiation therapy after lumpectomy, navigated participants (n = 255) were no mor

133 nstruction, adjuvant radiation therapy after lumpectomy, neoadjuvant chemotherapy for stage III disea

134 adjacent normal sections, obtained from the lumpectomy of 73 breast cancer patients.

135 Lumpectomy of pure LN lesions may not prevent malignancy

136 gery and 4342 [55.5%] of patients undergoing lumpectomy omitted RT).

137 cidental microscopic findings at the time of lumpectomy or core-needle biopsy.

138 nt breast lesions that traditionally require lumpectomy or excisional biopsy as search terms was cond

139 cal adipose deficiency, such as lipoatrophy, lumpectomy or facial trauma, is a formidable challenge i

140 ith localized DCIS were randomly assigned to lumpectomy or lumpectomy plus radiation (50 Gy).

141 Lumpectomy or mastectomy was performed in 71 women (79 i

142 METHODS After lumpectomy or mastectomy, women 60 years of age or young

143 patients immediately before their scheduled lumpectomy or mastectomy.

144 ctomy (OR, 1.43 [95% CI, 1.32-1.54]), breast lumpectomy (OR, 1.34 [95% CI, 1.23-1.46]), minimally inv

145 prepathology stratum, TARGIT concurrent with lumpectomy) or after lumpectomy (postpathology stratum,

146 nd rates of additional surgery after initial lumpectomy over time, and surgeon attitudes toward an ad

147 Lumpectomy patients received breast radiotherapy alone;

148 Independent predictors of LRR in lumpectomy patients were age, clinical nodal status (bef

149 All patients had planned lumpectomy, planned tangential whole-breast irradiation,

150 Lumpectomy plus adjuvant therapy with tamoxifen alone is

151 ts (8.9% local; 3.4% regional) and 10.3% for lumpectomy plus breast radiotherapy patients (8.1% local

152 DCIS were randomly assigned to lumpectomy or lumpectomy plus radiation (50 Gy).

153 w-up, our findings continue to indicate that lumpectomy plus radiation is more beneficial than lumpec

154 The benefit of lumpectomy plus radiation was virtually unchanged betwee

155 men with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy.

156 e early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy

157 TARGIT concurrent with lumpectomy) or after lumpectomy (postpathology stratum, TARGIT given subseque

158 herapy: randomisation occurred either before lumpectomy (prepathology stratum, TARGIT concurrent with

159 TARGIT concurrently with lumpectomy (prepathology, n=2298) had much the same resu

160 Recurrent tumors that occurred in the lumpectomy quadrant were more often similar in mammograp

161 involved with tumour, were randomly assigned lumpectomy, radiation therapy (50 Gy), and placebo (n=90

162 ion therapy (50 Gy), and placebo (n=902), or lumpectomy, radiation therapy, and tamoxifen (20 mg dail

163 The combination of lumpectomy, radiation therapy, and tamoxifen was effecti

164 domised controlled trial to find out whether lumpectomy, radiation therapy, and tamoxifen was of more

165 -negative breast cancer who are treated with lumpectomy, radiation, and adjuvant systemic therapy, th

166 tive sentinel lymph nodes (SLNs) who undergo lumpectomy, radiotherapy (RT), and systemic therapy.

167 Among patients who received lumpectomy, radiotherapy was associated with a reduction

168 end tests demonstrated an annual decrease in lumpectomy rates of 1.31% (95% CI, 1.30%-1.32%), 0.07% (

169 Lumpectomy rates reached a nadir between 2010 and 2013,

170 dicated a trend reversal with an increase in lumpectomy rates since 2013 and an associated decline in

171 From 2013 to 2017, the annual increase in lumpectomy rates was 0.96% (95% CI, 0.95%-0.98%), 1.60%

172 Lumpectomy rates were analyzed within study-defined risk

173 Conversely, in comparison with lumpectomy rates, overall mastectomy rates declined sign

174 factors were independent predictors of lower lumpectomy rates, prospective research is needed into ho

175 enetic counseling and testing, mastectomy vs lumpectomy, receipt of chest reconstruction, adjuvant ra

176 with a history of breast cancer treated with lumpectomy regardless of genetic predisposition; contral

177 tation of axillary lymph node dissection and lumpectomy reoperation in response to guidelines support

178 node dissection rates ranged from 7% to 47%, lumpectomy reoperation rates ranged from 3% to 62%, cont

179 gnificantly higher rate of TR/MM in both the lumpectomy + RT and lumpectomy alone groups.

180 lumpectomy alone group and 7.2 years for the lumpectomy + RT group.

181 % for lumpectomy alone and 8.0% and 9.2% for lumpectomy + RT, respectively.

182 Radiotherapy (RT) after lumpectomy significantly reduces the risk of recurrence.

183 eveloped microcalcifications confined to the lumpectomy site after more than 3 years.

184 rrences, 19 (70%) were at or adjacent to the lumpectomy site and eight (30%) were elsewhere in the br

185 urgery with adjuvant radiation that includes lumpectomy site boosts yields an acceptably low 5-year L

186 appearing microcalcifications develop at the lumpectomy site depending on time of appearance and numb

187 < or = 3 mm were more frequently found, and lumpectomy site radiation boost was used increasingly fr

188 east local recurrence away from the original lumpectomy site with or without postoperative standard w

189 eveloped microcalcifications confined to the lumpectomy site.

190 multifocal) underwent BCT, all with a single lumpectomy site.

191 tumor bed, for a total dose of 48 Gy to the lumpectomy site.

192 er standard pathology assessment of the main lumpectomy specimen (69.4% vs 38.2%, respectively).

193 The pathology of the lumpectomy specimen was reviewed for each patient to con

194 were compared with histologic findings from lumpectomy specimens to determine presence of intraducta

195 Of these lumpectomy specimens, 11 were identified with a positive

196 lcifications at the resection margins of the lumpectomy specimens, but had negative microscopic margi

197 gions were acquired from surgical margins of lumpectomy specimens, registered with ink, and correlate

198 Patients treated by lumpectomy that received RT had a superior OS compared w

199 the use of intraoperative irradiation after lumpectomy, the management of ductal carcinoma the effec

200 After lumpectomy, the saline-filled surgical cavity was assess

201 cm, IBTR occurs with enough frequency after lumpectomy to justify considering XRT, regardless of tum

202 Surgery after initial lumpectomy to obtain more widely clear margins is common

203 eceptor-positive breast carcinoma treated by lumpectomy to receive tamoxifen plus radiation therapy (

204 Among the lumpectomy-treated women whose surgical specimens had tu

205 Rates of final surgical procedure (lumpectomy, unilateral mastectomy, bilateral mastectomy)

206 ctomy (US dollars 2775 v US dollars 1849) or lumpectomy (US dollars 2112 v US dollars 1365) was used.

207 Significant predictors of lower lumpectomy usage were determined in multivariate analyse

208 Lumpectomy use declined with increasing tumor size and d

209 he following significant predictors of lower lumpectomy use: positive nodes; many positive nodes, inc

210 gram receipt were higher for women who had a lumpectomy (v mastectomy) and women who were white (v no

211 Younger or older age, lumpectomy (v mastectomy), and comorbidities were associ

212 Before randomization, lumpectomy was proposed for 86% of women with tumors < o

213 itial implant, and lasting 4 to 5 days after lumpectomy was prospectively evaluated in early-stage br

214 Overall, 12% more lumpectomies were performed in the preoperative group; i

215 Similarly, the rates of re-excision lumpectomy were also significantly lower during the B pe

216 r (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen p

217 who were candidates for either mastectomy or lumpectomy were recruited from a university breast cance

218 lateral breast tumor recurrence (IBTR) after lumpectomy were similar in both groups (7.9% and 5.8%, r

219 241,597 patients (76.4%) underwent a single lumpectomy, whereas 74,517 (23.6%) underwent at least 1

220 B-18, B-22, and B-25), who were treated with lumpectomy, whole-breast irradiation, and adjuvant syste

221 nt excisional biopsy (55.3%, n = 302/546) or lumpectomy (wide excision) (38.5%, n = 210/546).

222 Patients underwent lumpectomies with negative margins followed by whole bre

223 ts who underwent radiation therapy following lumpectomy with a planned electron boost were examined.

224 Eighty-five patients treated with BCT (lumpectomy with adjuvant radiation therapy) at the Medic

225 tus and by case treatment group: lumpectomy, lumpectomy with adjuvant radiation therapy, and mastecto

226 for all women undergoing mastectomy (MT) or lumpectomy with an axillary procedure (L-ANP).

227 n in patients treated by mastectomy (80%) or lumpectomy with axillary dissection and radiation (95%,

228 Two women underwent lumpectomy with breast irradiation.

229 positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole breast

230 positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole-breast

231 ast cancer who had undergone a mastectomy or lumpectomy with clear surgical margins.

232 and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells

233 carcinoma in situ, <=3 cm in size treated by lumpectomy with negative axillary nodes were randomly as

234 ated a randomized trial to determine whether lumpectomy with or without radiation therapy was as effe

235 Case participants who underwent lumpectomy with radiation reported lower levels of emoti

236 We have shown previously that lumpectomy with radiation therapy was more effective tha

237 She underwent a left lumpectomy with seed localization and sentinel lymph nod

238 and 22 mastectomy candidates were changed to lumpectomy, with tumor size decreasing from 4.2 +/- 2.1

239 TARGIT concurrent with lumpectomy within a risk-adapted approach should be cons

240 However, for patients undergoing lumpectomy without axillary surgery, it is an extra inva

241 with 39.2 percent in the women who underwent lumpectomy without irradiation (P<0.001).

242 receipt (only 45.0% in patients who received lumpectomy without radiotherapy).